Inga Deakin
Director at Anima
Inga Deakin
Director at Anima
London, England
Overview
Work Experience
Principal
2020 - Current
Investing in Healthtech, Life Sciences, TechBio in UK and Europe
Director
2023
Director
2023
Director
2023
Director
2021
Entrepreneur In Residence
2019 - 2020
Helping academic enterpreneurs commercialise products that they invent across specialising in medical devices and healthtech. EIR in Biomedical Engineering at Duke, consistently rated in the top 3 BME departments in the US. Mentor in Residence at Office of Licensing and Ventures, with 17 start-ups in 2020.
Chief of Staff
2017 - 2019
Liquid biopsy molecular diagnostics company in oncology. Based in the US coordinating operations as Chief of Staff as the company gained regulatory approval and initial sales into the US healthcare system.
Principal
2017 - 2018
In January 2017, the venture investment teams at Imperial Innovations changed name to Touchstone Innovations, which was acquired by IP Group PLC, a FTSE250 company, a few months later. Identifying, building and investing in life science companies - therapeutics, medical devices, diagnostics and healthcare companies including digital health.
Non Executive Director
2015 - 2017
Puridify, a bioprocessing company, was acquired by GE Healthcare in November 2017 https://www.touchstoneinnovations.com/news-room/2017/nov/28/portfolio-company-puridify-acquired-ge-healthcare/
Board Observer
2014 - 2015
Board Observer
2016 - 2017
Haemophilia drug development company. Innovations co-led a £14m Series A in 2016 with Medicxi to fund development of SerpinPC to treat haemophilia. In October 2019, the company started its PhaseI/II study. http://apcintex.com/